OPGN: OpGen Quarterly EPS earnings growth

Public company logo of OpGen, Inc. (OPGN)

OpGen, Inc. is experiencing an acute efficiency crisis, selling off patents to settle its obligations. This quarterly EPS trend clearly demonstrates this decline, where the 0.00 mark characterizes the current profit level. The business relies on the sale of Acuitas molecular tests, and cash flows depend on the adoption rate of diagnostic systems in clinics.

OpGen Inc (OPGN) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 08/31/2024

Summary analytical data breakdowns for OpGen Corporation (OPGN)

- share price and expert price forecast:
Stock Price OpGen|OPGN - Forecast Levels Chart
- market capitalization information:
Market Capitalization OpGen Corp|OPGN - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share OpGen|OPGN - Company Net Assets|Market Cap to Net Assets Ratio opgen.com|OPGN - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital OpGen, Inc.|OPGN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity OpGen, Inc.|OPGN - Company Cumulative Debt|Debt to Book Capitalization Ratio OpGen Corp|OPGN - Company Long-Term Indebtedness|Company Short-Term Debt OpGen|Quick Liquidity opgen.com
- earnings and valuation multiples indicators:
OPGN - Company Net Income|Expected Profit OpGen, Inc.|OPGN - Market Cap to Net Income|Forward P/E Multiple OpGen Corp|OPGN - Price to Net Income Growth Ratio|EV/EBITDA Multiple OpGen Corp|OPGN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months OpGen|OPGN - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months opgen.com|OPGN - Earnings per share increase in current year|Earnings growth forecast for next year OpGen, Inc.
- revenue and sales proceeds data:
OPGN - Company Gross Revenue|Company Projected Revenue OpGen|OPGN - Market Cap to Revenue Ratio|Forward P/S Multiple OpGen Corp
Comprehensive company analysis:OpGen, Inc.
Flagship merchandise of OpGen, Inc.

The total loss of OpGen, Inc. (OPGN) positions in molecular diagnostics and a prolonged solvency crisis make the calculation of net income per share a critical indicator of business survival. This metric captures the percentage change in profit per quarter, reflecting the company's ability to generate income, which, in the dynamics of quarterly EPS, allows for the timely detection of regulatory risks and a dangerous contraction of capital.

Key competitors

SMMT: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months MRNA (Moderna Inc)|PCVX (Vaxcyte Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tarsus Corp TARS|Quarterly EPS earnings growth CRMD|Year-over-year net earnings per share growth for the last 12 months serestherapeutics.com MCRB|Spero Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months SCYX (SCYNEXIS Inc)|AN2 Bio - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months PolyPid Ltd. PYPD|LakeShore Biopharma Co. (LSB) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Iterum Therapeutics (ITRM)|Year-over-year earnings per share growth for the last twelve months BiomX Inc|Year-over-year earnings per share growth for the last 12 months SNGX (BioPharma Bio)|Year-over-year earnings per share growth for the last twelve months 60 Degrees Pharmaceuticals (SXTP)|Year-over-year net earnings per share change for the last twelve months oragenics.com